Stability of gut microbiome after COVID-19 vaccination in healthy and immuno-compromised individuals.


Journal

Life science alliance
ISSN: 2575-1077
Titre abrégé: Life Sci Alliance
Pays: United States
ID NLM: 101728869

Informations de publication

Date de publication:
Apr 2024
Historique:
received: 13 12 2023
revised: 27 12 2023
accepted: 29 12 2023
medline: 6 2 2024
pubmed: 6 2 2024
entrez: 5 2 2024
Statut: epublish

Résumé

Bidirectional interactions between the immune system and the gut microbiota are key contributors to various physiological functions. Immune-associated diseases such as cancer and autoimmunity, and efficacy of immunomodulatory therapies, have been linked to microbiome variation. Although COVID-19 infection has been shown to cause microbial dysbiosis, it remains understudied whether the inflammatory response associated with vaccination also impacts the microbiota. Here, we investigate the temporal impact of COVID-19 vaccination on the gut microbiome in healthy and immuno-compromised individuals; the latter included patients with primary immunodeficiency and cancer patients on immunomodulating therapies. We find that the gut microbiome remained remarkably stable post-vaccination irrespective of diverse immune status, vaccine response, and microbial composition spanned by the cohort. The stability is evident at all evaluated levels including diversity, phylum, species, and functional capacity. Our results indicate the resilience of the gut microbiome to host immune changes triggered by COVID-19 vaccination and suggest minimal, if any, impact on microbiome-mediated processes. These findings encourage vaccine acceptance, particularly when contrasted with the significant microbiome shifts observed during COVID-19 infection.

Identifiants

pubmed: 38316462
pii: 7/4/e202302529
doi: 10.26508/lsa.202302529
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024 Boston et al.

Auteurs

Rebecca H Boston (RH)

https://ror.org/013meh722 Medical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK.

Rui Guan (R)

https://ror.org/013meh722 Medical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK.

Lajos Kalmar (L)

https://ror.org/013meh722 Medical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK.

Sina Beier (S)

https://ror.org/013meh722 Medical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK.

Emily C Horner (EC)

https://ror.org/013meh722 Medical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK.

Nonantzin Beristain-Covarrubias (N)

https://ror.org/013meh722 Medical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK.

Juan Carlos Yam-Puc (JC)

https://ror.org/013meh722 Medical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK.

Pehuén Pereyra Gerber (P)

https://ror.org/013meh722 Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge, UK.
https://ror.org/013meh722 Department of Medicine, University of Cambridge, Cambridge, UK.

Luisa Faria (L)

https://ror.org/013meh722 Medical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK.

Anna Kuroshchenkova (A)

https://ror.org/013meh722 Medical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK.

Anna E Lindell (AE)

https://ror.org/013meh722 Medical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK.

Sonja Blasche (S)

https://ror.org/013meh722 Medical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK.

Andrea Correa-Noguera (A)

Department of Clinical Immunology, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK.

Anne Elmer (A)

NIHR Cambridge Clinical Research Facility, Cambridge, UK.

Caroline Saunders (C)

NIHR Cambridge Clinical Research Facility, Cambridge, UK.

Areti Bermperi (A)

NIHR Cambridge Clinical Research Facility, Cambridge, UK.

Sherly Jose (S)

NIHR Cambridge Clinical Research Facility, Cambridge, UK.

Nathalie Kingston (N)

NIHR BioResource, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Sofia Grigoriadou (S)

Department of Clinical Immunology, Barts Health, London, UK.

Emily Staples (E)

https://ror.org/013meh722 Medical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK.

Matthew S Buckland (MS)

Department of Clinical Immunology, Barts Health, London, UK.
UCL GOSH Institute of Child Health Division of Infection and Immunity, Section of Cellular and Molecular Immunology, London, UK.

Sara Lear (S)

Department of Clinical Immunology, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK.

Nicholas J Matheson (NJ)

https://ror.org/013meh722 Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge, UK.
https://ror.org/013meh722 Department of Medicine, University of Cambridge, Cambridge, UK.
NHS Blood and Transplant, Cambridge, UK.

Vladimir Benes (V)

European Molecular Biology Laboratory, Heidelberg, Germany.

Christine Parkinson (C)

Department of Clinical Immunology, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK.

James Ed Thaventhiran (JE)

https://ror.org/013meh722 Medical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK jedt2@mrc-tox.cam.ac.uk.
Department of Clinical Immunology, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK.

Kiran R Patil (KR)

https://ror.org/013meh722 Medical Research Council Toxicology Unit, University of Cambridge, Cambridge, UK kp533@mrc-tox.cam.ac.uk.

Classifications MeSH